Why an Unexpected Result Needs Triage
A concentration that is unexpectedly high or low is a signal to investigate, not an explanation by itself. It may reflect a real change in drug exposure, but it may also be the predictable consequence of a missed dose, a sample collected at an unplanned time, a compromised specimen, or a limitation of the assay. These possibilities call for different interpretations. Acting on the number before checking them can turn a correct measurement into a mistaken clinical conclusion.
The first question is whether the patient needs prompt clinical assessment. Symptoms or other evidence of toxicity or loss of effect should be considered on their own merits; a concentration result does not override them. If the patient is clinically stable, the next task is to find out whether the result is comparable with the intended target. A target may apply only to a particular sampling time, dosing regimen, or clinical context. A value cannot be classified meaningfully as high or low against that target until those conditions are checked.
Triage is not a substitute for clinical judgment, and it does not determine a dose change by itself. Its purpose is to establish what the result can and cannot tell us. The earlier material on missed or delayed doses, sampling time, analytical uncertainty, specimen contamination, and minimum metadata provides relevant concepts; here they are brought together into a practical diagnostic sequence.
A Diagnostic Sequence
Work from the circumstances that can invalidate interpretation toward explanations that require more pharmacological or analytical investigation. Record what is known and what remains uncertain rather than silently assuming that the intended dose and sample time occurred.
Check for current signs or symptoms that require timely clinical attention. Do not wait for a concentration to explain a concerning clinical state.
Verify the drug, analyte, units, target, and intended sampling condition. A peak, trough, or other timed target is not interchangeable with a measurement collected at a different phase.
Check what was actually taken or administered, when it was taken, and whether doses were missed, delayed, duplicated, or changed. Distinguish the recorded regimen from the actual history.
Compare the actual sample time with the last dose, the next scheduled dose, and any infusion or absorption phase relevant to the drug. Ask whether the collection procedure could have affected the sample.
Check identity, handling, possible contamination, units, assay method, measurement range, and known interferences or cross-reactivity. Consult method-specific information rather than assuming all assays behave alike.
State the unresolved question. Another measurement is potentially useful only if its collection or method can address that question; repeating the same measurement under the same problematic conditions may simply reproduce the uncertainty.
The order is a guide, not a rigid rule. For example, a suspected sample mix-up may be checked as soon as it is noticed. The key is to separate the questions: was the patient’s exposure unexpected, was the sample representative of that exposure, and did the assay measure the intended analyte reliably?
Timing and Dose History: Check Comparability First
Many concentration targets are defined for a particular time relative to a dose. If a sample is collected earlier or later than intended, it may be numerically higher or lower without indicating a change in the patient’s underlying clearance or an error in the assay. The pharmacokinetic expectation depends on the drug and regimen: a sample during absorption, after an infusion, or during elimination has a different interpretation. Do not apply a simple elimination calculation during absorption or to a concentration that is not described by the assumed model.
A useful calculation is sometimes possible during terminal elimination. Under a one-compartment, first-order elimination approximation, with no further input of drug over the interval, concentration declines exponentially. If the elimination half-life is \(t_{1/2}\), the concentration after an additional time \(\Delta t\) is:
This follows because first-order elimination gives \(C(t+\Delta t)=C(t)e^{-k\Delta t}\), and the half-life relation is \(t_{1/2}=\ln(2)/k\). Substituting \(k=\ln(2)/t_{1/2}\) gives \(e^{-\ln(2)\Delta t/t_{1/2}}=2^{-\Delta t/t_{1/2}}\). This is a check on plausibility, not a universal correction formula: ongoing absorption, additional doses, multicompartment distribution, nonlinear pharmacokinetics, or an unsuitable half-life can make it misleading.
Worked Example: A “High Trough” Collected Too Early
Hypothetical case. For a drug with a target trough of 8–12 mg/L, a result of 16.8 mg/L is reported as a trough. The dose record and patient interview indicate that the sample was actually collected 6 hours after a dose; the intended trough was 12 hours after that dose. Assume, only for this check, that absorption was complete and terminal elimination is first-order with a half-life of 8 hours.
The sample is 6 hours earlier than the intended trough. Under the stated elimination assumptions, the expected concentration at the intended time is:
The estimated value at 12 hours is about 10.0 mg/L, within the hypothetical target range. The measured 16.8 mg/L should therefore not be treated as a valid trough comparison. This calculation does not prove the patient’s true trough was 10.0 mg/L: it depends on the assumptions, the dose history, and the stated half-life. The immediate finding is that the sample was collected at the wrong time for the intended comparison.
Dose history is equally important. A concentration may be lower than expected because a dose was missed or delayed, or higher because an extra dose was taken. Check the actual events with the patient, caregiver, administration record, and relevant documentation where available. If accounts conflict, preserve that uncertainty. A scheduled regimen alone does not establish that the scheduled doses were taken.
Worked Example: A Low Result After a Missed Dose
Hypothetical case. A patient’s prior intended trough was 8.0 mg/L, measured 12 hours after the last dose. The next dose was missed, and a new sample was collected 36 hours after that same last dose. The observed result is 0.60 mg/L. Assume the drug was in terminal elimination after the first sample, no drug was taken or administered in between, and the elimination half-life is 6 hours.
The interval from the intended trough time to the new sample time is \(36-12=24\) hours, or \(24/6=4\) half-lives. The simple elimination expectation is:
The observed 0.60 mg/L is close to this illustrative expectation. The low result is therefore compatible with the documented missed dose and longer interval since the last dose; it does not, by itself, establish that the regular regimen produced inadequate exposure. The calculation assumes first-order elimination over the interval and a comparable concentration of 8.0 mg/L at 12 hours. If absorption was incomplete, the half-life is inappropriate, or the dose history is uncertain, this comparison may not hold.
Specimen and Assay: Is the Number Measuring What It Appears to Measure?
A correctly timed sample can still be unrepresentative or analytically misleading. Check whether the sample was drawn from a site that could have been exposed to drug-containing fluid, whether the tube and patient identity are correct, and whether collection, transport, and storage meet the assay’s requirements. A suspiciously high result from a line used to administer the drug, for example, raises a different question from a high result in a properly collected peripheral sample. Do not infer the patient’s circulating concentration from a possibly contaminated specimen.
Next, confirm the reported units and analyte. A concentration in micrograms per litre is numerically different from the same concentration in milligrams per litre, even though the physical quantity can be converted. Also establish whether the result refers to parent drug, a metabolite, or a combined signal. Assay performance matters: a method can have a limited measurement range, known interference, or cross-reactivity with related compounds. An assay result should be interpreted using the method actually used, not a generic assumption about “the test.”
Worked Example: An Assay Signal Includes a Metabolite
Hypothetical case. A patient’s concentration is unexpectedly reported as 24 mg/L by an assay whose documented response is 100% to the parent drug and 50% to a specified metabolite, expressed as parent-drug equivalents. A method-specific confirmatory measurement reports 8 mg/L of parent drug and 32 mg/L of that metabolite. Assume these concentrations are within the validated measurement ranges and the stated cross-reactivity applies to this sample.
The assay’s expected reported signal, in parent-drug equivalents, is:
The 24 mg/L result is consistent with the assay responding to both compounds. It is not evidence that the parent-drug concentration itself is 24 mg/L. The appropriate interpretation depends on which analyte the clinical question concerns and on the validated method. Repeating the same assay without changing the method may reproduce the same combined signal; it would not, on its own, separate parent drug from metabolite.
When Another Measurement Could Help
A repeat or alternative measurement is most informative when it addresses a specific unresolved uncertainty. If the concern is incorrect sample timing, a properly timed collection can address comparability. If sample contamination or identity is in question, a new, independently collected specimen may address specimen validity. If the assay may be responding to another compound, a method with suitable selectivity may address analyte identity. These are different questions, so “repeat the test” is not a complete plan.
A repeat result may add little if the same uncertainty remains: for example, another sample drawn at the wrong time, another specimen from a potentially contaminated line, or the same assay in the presence of the same interference. Likewise, a second measurement that agrees with the first does not automatically prove that either is clinically representative. The value of new information depends on what changed and what uncertainty it was intended to reduce. The detailed decision of whether and how to repeat a measurement is a separate question.
Common Pitfalls and Practical Limits
| Wrong reasoning | Correction |
|---|---|
| “The result is above the target, so the patient’s exposure must be too high.” | First verify that the target applies to this analyte, dose history, and sampling time; then assess specimen and assay validity. |
| “The prescribed dose was unchanged, so dosing cannot explain the result.” | A prescription does not establish actual administration. Check missed, delayed, duplicated, or otherwise changed doses. |
| “The repeat result matched, so the first result must be valid.” | Repeated measurements can share the same timing error, collection problem, or assay limitation. Ask what the repeat actually tested. |
| “A simple half-life calculation gives the corrected concentration.” | Such a calculation is conditional on the elimination model and timing assumptions. It is not appropriate when those assumptions fail. |
Triage can narrow the explanations, but it cannot guarantee that one cause has been identified. Dose histories may be incomplete; sample documentation may be ambiguous; and assay limitations may not be fully characterized. More than one factor can contribute at once. Document the facts, assumptions, and unresolved uncertainties, and interpret the result in the patient’s clinical context rather than treating a single number as a complete account of exposure.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- A hypothetical drug has a target trough of 5–10 mg/L. A result of 14 mg/L was collected 4 hours after a dose, but the target is defined for a sample immediately before the next dose. What should be checked before classifying the result?
- A sample taken at 12 hours is 6.0 mg/L. Under a first-order elimination assumption with a 6-hour half-life and no further drug input, what concentration is expected 18 hours later?
- An unexpectedly low result follows a documented missed dose. Does that alone show that the prescribed regimen is inadequate? Why or why not?
- A result is unexpectedly high, and the sample was collected from a line used to administer the drug. What is the principal concern, and what would a useful new measurement need to address?
- Why might repeating the same assay be unhelpful when a known metabolite cross-reacts with it?
Solutions. (1) Confirm the actual dose history and exact collection time, then assess whether the sample can be compared with a trough target; 4 hours after a dose is not the specified pre-dose condition. (2) The additional interval is 18 hours, or three half-lives, so \(6.0\times 2^{-18/6}=6.0/8=0.750\) mg/L. This is an expectation only under the stated assumptions. (3) No. The result may be explained by the longer interval since the last actual dose; it does not by itself establish exposure under the prescribed regimen. (4) Drug-containing fluid may have contaminated the specimen, making it unrepresentative of circulating concentration. A useful new measurement would need an independently collected specimen that avoids the suspected contamination. (5) The same assay may respond to the same metabolite again, reproducing a combined signal rather than resolving the parent-drug concentration.